PRANEU 652 No.

of Pages 6

Autogreffe de cellules souches hématopoïétiques en neurologie

inflammatoire
Histoire de la neurologie

Déclaration de liens d'intérêts patients after autologous hematopoietic stem cell transplantation.
H. Zephir déclare ne pas avoir de liens d'intérêts. Clin Immunol 2016;169:47–57.
H. Zephir a reçu des honoraires d'expertises par Biogen Idec, Alexion, [15] Tolf A, Fagius J, Carlson K, Åkerfeldt T, Granberg T, Larsson
Horizon Therapeutics, Sanofi, Novartis, BMS, Merck, Roche et a été EM, et al. Sustained remission in multiple sclerosis after hema-
invitée à des congrès nationaux et internationaux par Roche, BMS, topoietic stem cell transplantation. Acta Neurol Scand
Biogen Idec, Merck et Alexion. 2019;140:320–7.
[16] Bowen JD, Kraft GH, Wundes A, Guan Q, Maravilla KR, Gooley
TA, et al. Autologous hematopoietic cell transplantation following
high-dose immunosuppressive therapy for advanced multiple
RÉFÉRENCES sclerosis: long-term results. Bone Marrow Transplant
2012;47:946–51.
[1] Armitage JO. Bone marrow transplantation. N Engl J Med [17] Carreras E, Saiz A, Marín P, Martínez C, Rovira M, Villamor N,
1994;330:827–38. et al. CD34+ selected autologous peripheral blood stem cell
[2] Blanco Y, Saiz A, Carreras E, Graus F. Autologous haemato- transplantation for multiple sclerosis: report of toxicity and treat-
poietic-stem-cell transplantation for multiple sclerosis. Lancet ment results at one year of follow-up in 15 patients. Haematolo-
Neurol 2005;4:54–63. gica 2003;88:306–14.
[3] Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, [18] Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I,
Saccardi R. Autologous haematopoietic stem cell transplantation Kimiskidis V, et al. Peripheral blood stem cell transplantation in
for treatment of multiple sclerosis. Nat Rev Neurol 2017;13:391– the treatment of progressive multiple sclerosis: first results of a
405. pilot study. Bone Marrow Transplant 1997;20:631–8.
[4] Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, [19] Burt RK, Traynor AE, Cohen B, Karlin KH, Davis FA, Stefoski D,
Marjanovic Z, et al. Evolution, trends, outcomes and economics et al. T cell-depleted autologous hematopoietic stem cell trans-
of hematopoietic stem cell transplantation in severe autoimmune plantation for multiple sclerosis: report on the first three patients.
diseases. Blood Adv 2017;1:2742–55. Bone Marrow Transplant 1998;21:537–41.
[5] Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant [20] Mancardi GL, Saccardi R, Filippi M, Gualandi F, Murialdo A,
human granulocyte colony stimulating factor in patients with sys- Inglese M, et al. Autologous hematopoietic stem cell transplanta-
temic lupus erythematosus associated neutropenia and refractory tion suppresses Gd-enhanced MRI activity in MS. Neurology
infections. J Rheumatol 1997;24:2153–7. 2001;57:62–8.
[6] Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, [21] Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla
et al. Multiple sclerosis flares associated with recombinant gra- KR, Park M, et al. High-dose immunosuppressive therapy and
nulocyte colony-stimulating factor. Neurology 2000;54:2147–50. autologous peripheral blood stem cell transplantation for severe
[7] Bakhuraysah MM, Siatskas C, Petratos S. Hematopoietic stem multiple sclerosis. Blood 2003;102:2364–72.
cell transplantation for multiple sclerosis: is it a clinical reality ? [22] Fassas A, Kimiskidis VK, Sakellari I, Kapinas K, Anagnosto-
Stem Cell Res Ther 2016;7:12. poulos A, Tsimourtou V, et al. Long-term results of stem cell
[8] Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, transplantation for MS: a single-center experience. Neurology
et al. Recommended screening and preventive practices for long- 2011;76:1066–70.
term survivors after hematopoietic cell transplantation. Bone Mar- [23] Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ,
row Transplant 2012;47:337–41. Hendrawan K, et al. Prospective phase II clinical trial of auto-
[9] DeFilipp Z, Duarte R, Snowden J, Majhail N, Greenfield D, logous haematopoietic stem cell transplant for treatment refrac-
Miranda J, et al. Metabolic syndrome and cardiovascular disease tory multiple sclerosis. J Neurol Neurosurg Psychiatry
following hematopoietic cell transplantation: screening and pre- 2019;90:514–21.
ventive practice recommendations from CIBMTR and EBMT. [24] Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson
Bone Marrow Transplant 2017;52:173–82. M, Nilsson P, et al. Autologous haematopoietic stem cell trans-
[10] Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, plantation for aggressive multiple sclerosis: the Swedish expe-
Cervera R, et al. Haematopoietic SCT in severe autoimmune rience. J Neurol Neurosurg Psychiatry 2014;85:1116–21.
diseases: updated guidelines of the European Group for Blood [25] Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM,
and Marrow Transplantation. Bone Marrow Transplant Steinmiller KC, et al. High-dose immunosuppressive therapy
2012;47:770–90. and autologous HCT for relapsing-remitting MS. Neurology
[11] Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, 2017;88:842–52.
Cassiani-Ingoni R, et al. Thymic output generates a new and [26] Mariottini A, Innocenti C, Forci B, Magnani E, Mechi C,
diverse TCR repertoire after autologous stem cell transplantation Barilaro A, et al. Safety and efficacy of autologous hemato-
in multiple sclerosis patients. J Exp Med 2005;201:805–16. poietic stem-cell transplantation following natalizumab dis-
[12] Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, continuation in aggressive multiple sclerosis. Eur J Neurol
Desmarais C, et al. Tcell repertoire following autologous stem cell 2019;26:624–30.
transplantation for multiple sclerosis. J Clin Invest [27] Das J, Snowden J, Burman J, Freedman M, Atkins H, Bowman
2014;124:1168–72. M, et al. Autologous haematopoietic stem cell transplantation as a
[13] Karnell FG, Lin D, Motley S, Duhen T, Lim N, Campbell DJ, et al. first-line disease-modifying therapy in patients with aggressive
Reconstitution of immune cell populations in multiple sclerosis multiple sclerosis. Mult Scler Houndmills Basingstoke Engl
patients after autologous stem cell transplantation. Clin Exp 2021;27:1198–204.
Immunol 2017;189:268–78. [28] Burt RK, Loh Y, Cohen B, Stefosky D, Balabanov R, Katsamakis
[14] Arruda LCM, de Azevedo JTC, de Oliveira GLV, Scortegagna G, et al. Autologous non-myeloablative haemopoietic stem cell
GT, Rodrigues ES, Palma PVB, et al. Immunological correlates transplantation in relapsing-remitting multiple sclerosis: a phase I/
of favorable long-term clinical outcome in multiple sclerosis II study. Lancet Neurol 2009;8:244–53.

Pour citer cet article : Zéphir H. Autogreffe de cellules souches hématopoïétiques en neurologie inflammatoire.
Pratique Neurologique – FMC (2023), [Link]